Several studies have shown that high-dose chemotherapy is not able to modify the poorer prognosis of HER-2-positive breast cancer patients (Slamon et al, 1987; Bitran et al, 1996; Nieto et al, 2002; Rodenhuis et al, 2003; Guarneri et al, 2004). Here, ERBB2 is linked to breast cancer.